12 Best Small Cap Stocks to Buy for Long Term
Tom Lee of Fundstrat told CNBC on June 9 that market jitters are tied to the run-up to SpaceX’s $75 billion Nasdaq 100 IPO and ongoing tech capital raises, but he views consolidation as healthy. The article screens small caps with 5-year sales growth >30% and lists 12 hedge-fund favorites (data June 15), including Nanobiotix (€42.1m cash; €86.1m follow-on) and Agilon (Barclays $81; Benchmark $95).
How this was made
The 30-second read
Why it matters
The only concrete, trader-relevant items are (1) NBTX’s follow-on offering and FDA acceptance of a protocol amendment plus new trial data presentation, and (2) AGL’s analyst upgrade/price-target increases tied to improved value-based care outlook and de-risked estimates.
Market read
This is more of a long-term stock-pick roundup than a fresh market-moving newswire; it provides incremental catalysts for NBTX and AGL but lacks same-day, market-wide triggers.
What to watch
For NBTX, the article emphasizes cash runway and protocol mechanics but not clinical efficacy magnitude; for AGL, the PTs hinge on Medicare Advantage rate outcomes and cost trend stabilization that may still be uncertain.
Background
The piece is a promotional-style list of “best small cap stocks,” using hedge-fund sentiment and a screener, with brief company catalysts and analyst notes.
Ticker impact
Nanobiotix reported Q1 2026 cash runway into 2029, completed a May follow-on offering, and disclosed new J&J trial/FDA protocol-amendment details.
Moderate near-term volatility possible around biotech trial/FDA headline digestion; direction uncertain without efficacy readout.
The article includes concrete capital raise and FDA acceptance/protocol amendment, but does not provide efficacy outcomes—so impact is more about risk/timeline than immediate sales upside.
Agilon Health received analyst rating/price-target upgrades (Barclays to Equal Weight; Benchmark Buy with higher PT) citing improved value-based care outlook and de-risked estimates.
Potentially supportive bias for the stock over days/weeks, though magnitude depends on how much the market already priced the upgrades.
The text provides explicit PT changes and the stated thesis (stabilizing cost trends, 2027 MA rate outcome, de-risked forward estimates), which are actionable for traders; however, it’s still analyst-driven rather than a new print from the company.
Market effects
Biotech and value-based care narratives get incremental support via trial/protocol updates and analyst re-ratings, but no broad sector catalyst is disclosed.
No specific regional macro or policy catalyst beyond general market jitters framing.
No direct global linkage beyond multinational trial sponsorship context (J&J) and FDA acceptance.
Counterpoint
Analyst upgrades and protocol amendments may not translate into near-term price follow-through without efficacy/endpoint data; financing news can also signal dilution risk.
Key entities
- public_companyNanobiotix S.A.
Late-stage oncology biotech; disclosed Q1 2026 cash runway, May follow-on offering proceeds, and FDA acceptance of a protocol amendment for J&J-sponsored studies.
- public_companyAgilon Health, Inc.
Value-based care/healthcare services company; received Barclays and Benchmark rating/price-target upgrades citing stabilizing cost trends and improved 2027 Medicare Advantage outlook.
